{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:03:24Z","timestamp":1788393804358,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Eli Lilly Sweden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40487-024-00324-0","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T09:35:12Z","timestamp":1739525712000},"page":"185-200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Observational Study of Incidence and Outcomes in an HR+\/HER2\u2013 Early Breast Cancer Population with High-Risk of Recurrence in Finland"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6484-1365","authenticated-orcid":false,"given":"Ravinder","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1879-0739","authenticated-orcid":false,"given":"Samuli","family":"Tuominen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0511-3939","authenticated-orcid":false,"given":"Mariann I.","family":"Lassenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merja","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Torstensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9384-9614","authenticated-orcid":false,"given":"Tom","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"issue":"3","key":"324_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"324_CR2","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1158\/1055-9965.EPI-15-0535","volume":"24","author":"CE DeSantis","year":"2015","unstructured":"DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International Variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomark Prev. 2015;24(10):1495\u2013506.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"324_CR3","unstructured":"The Finnish Cancer Registry. Cancer in Finland 2021 [Available from: https:\/\/cancerregistry.fi\/statistics\/cancer-statistics\/. Accessed 10 Nov 2023."},{"issue":"10","key":"324_CR4","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1093\/annonc\/mdz189","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(10):1674.","journal-title":"Ann Oncol"},{"issue":"1","key":"324_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.","journal-title":"Nat Rev Dis Primers"},{"issue":"19","key":"324_CR6","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836\u201346.","journal-title":"N Engl J Med"},{"key":"324_CR7","doi-asserted-by":"publisher","unstructured":"Gerber B, Freund M, Reimer T. Recurrent Breast Cancer Deutsches Aerzteblatt Online2010 [updated 12 February 2010. Available from: https:\/\/doi.org\/10.3238\/arztebl.2010.0085.","DOI":"10.3238\/arztebl.2010.0085"},{"issue":"Suppl 3","key":"324_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.10-90003-20","volume":"10","author":"J O'Shaughnessy","year":"2005","unstructured":"O\u2019Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20\u20139.","journal-title":"Oncologist"},{"issue":"1","key":"324_CR9","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1093\/oncolo\/oyac234","volume":"28","author":"M Toi","year":"2023","unstructured":"Toi M, Boyle F, Im YH, Reinisch M, Molthrop D, Jiang Z, et al. Adjuvant abemaciclib combined with endocrine therapy: efficacy results in monarchE cohort 1. Oncologist. 2023;28(1):e77\u201381.","journal-title":"Oncologist"},{"issue":"1","key":"324_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-021-01393-z","volume":"23","author":"ALV Johansson","year":"2021","unstructured":"Johansson ALV, Trewin CB, Fredriksson I, Reinertsen KV, Russnes H, Ursin G. In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study. Breast Cancer Res. 2021;23(1):17.","journal-title":"Breast Cancer Res"},{"issue":"34","key":"324_CR11","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib Combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (Monarche). j Clin Oncol. 2020;38(34):3987\u201398.","journal-title":"j Clin Oncol"},{"issue":"1","key":"324_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77\u201390.","journal-title":"Lancet Oncol"},{"key":"324_CR13","doi-asserted-by":"publisher","first-page":"S1256","DOI":"10.1016\/j.annonc.2023.10.007","volume":"34","author":"N Harbeck","year":"2023","unstructured":"Harbeck N, Rastogi P, O\u2019Shaughnessy J, Boyle F, Cortes J, Rugo HS, et al. Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. Ann Oncol. 2023;34:S1256.","journal-title":"Ann Oncol"},{"key":"324_CR14","unstructured":"European Medicines Agency (2023) Summary of Product Characteristics for Verzenios. Verzenios, INN-abemaciclib. Retrieved from http:\/\/www.ema.europa.eu. Accessed 8 Jan 2024"},{"issue":"2","key":"324_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264637","volume":"17","author":"DR Nelson","year":"2022","unstructured":"Nelson DR, Brown J, Morikawa A, Method M. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics. PLoS ONE. 2022;17(2): e0264637.","journal-title":"PLoS ONE"},{"issue":"21","key":"324_CR16","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.2217\/fon-2022-0310","volume":"18","author":"KM Sheffield","year":"2022","unstructured":"Sheffield KM, Peachey JR, Method M, Grimes BR, Brown J, Saverno K, et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncol. 2022;18(21):2667\u201382.","journal-title":"Future Oncol"},{"key":"324_CR17","doi-asserted-by":"publisher","first-page":"S285","DOI":"10.1016\/j.annonc.2023.09.453","volume":"34","author":"Y Fan","year":"2023","unstructured":"Fan Y, Ji D, Jiang M, Tan Y, Yang Y, Li T, et al. Evolution and risk stratification of adjuvant treatment strategies for early breast cancer: a Chinese perspective based on a national cancer database. Ann Oncol. 2023;34:S285\u20136.","journal-title":"Ann Oncol"},{"issue":"15","key":"324_CR18","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1200\/JCO.2006.10.3523","volume":"25","author":"CA Hudis","year":"2007","unstructured":"Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25(15):2127\u201332.","journal-title":"J Clin Oncol"},{"issue":"6","key":"324_CR19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382.","journal-title":"Am J Epidemiol"},{"key":"324_CR20","unstructured":"R Core Team R. A Language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017. Available from: https:\/\/www.R-project.org\/. Accessed 21 Nov 2023."},{"issue":"2","key":"324_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andre F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(2):159\u201382.","journal-title":"Ann Oncol"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-024-00324-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-024-00324-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-024-00324-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T10:56:34Z","timestamp":1741085794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-024-00324-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["324"],"URL":"https:\/\/doi.org\/10.1007\/s40487-024-00324-0","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was funded by Eli Lilly Sweden. Funding source participated in study concept\/design, interpretation of results, writing of the manuscript and the decision to submit the paper for publication. Samuli Tuominen and Mariann I. Lassenius are employed by Medaffcon Oy (Espoo, Finland), which received payments from Eli Lilly (Sweden) for conducting the study. Ravinder Singh is employed by Eli Lilly and Company, Oslo, Norway. Merja Auvinen is an employee of Medaffcon who was contracted by Eli Lilly Company (Helsinki, Finland) during the conduct of the study. Astrid Torstensson is employed by Eli Lilly and Company, Solna, Sweden. Tom Wiklund reports personal fees from Eli Lilly Finland for Scientific Committee participation during study conduct, personal fees from Eli Lilly, Seagen, MSD, outside the submitted work, and participation in Advisory Board of Novartis and Gilead outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This non-interventional, retrospective register study was conducted in accordance with the Declaration of Helsinki and the Act on Secondary Use of Health and Social Data 552\/2019, Finland. The study permission was granted by the Finnish Social and Health Data Permit Authority Findata (permission number THL\/6325\/14.02.00\/2020). Ethical approval and written informed consents were not needed as the present study was based on secondary use of register data, as authorized by Findata in accordance with the Act on Secondary Use of Health and Social Data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}